Pfizer's Strategic Pivot to Weight-Loss Drugs Fuels Investor Confidence

After a challenging period marked by declining COVID-19-related revenue and patent expirations, Pfizer is making a concerted push into the lucrative obesity drug market. This strategic shift, powered by a recent acquisition and promising clinical data, is helping the pharmaceutical giant regain its footing with investors.

A Potential Edge: Monthly Dosing Regimen

The company's renewed focus on metabolic diseases is showing tangible progress. Following the discontinuation of its internal GLP-1 drug candidate in April 2025, Pfizer moved swiftly to re-enter the field by acquiring developer Metsera in November of that year. The strategy is already yielding results.

Recent Phase 2b trial data for the candidate PF'3944, known as the VESPER-3 study, demonstrated significant weight reduction. Crucially, it also revealed a potential operational advantage. Unlike established competitors such as Wegovy or Zepbound, which require weekly injections, the Pfizer drug is designed for monthly administration after an initial phase. To support a planned 2028 approval, the company has scheduled the initiation of more than 20 additional obesity studies this year.

Should investors sell immediately? Or is it worth buying Pfizer?

Broader Stabilization: Policy and Pipeline

Beyond its metabolic disease pipeline, other factors are contributing to a more stable outlook for Pfizer. The company's oncology research portfolio provides a solid foundation for future growth. Furthermore, a significant political agreement has mitigated a key risk. Pfizer secured a three-year exemption from potential tariffs through a deal with the White House, in exchange for committing to substantial investments in U.S.-based research and capital projects.

This combination of clinical progress and operational de-risking is reflected in the market. On Monday, the share price reached a new 52-week high of €24.18, extending its year-to-date gain to over 12 percent.

Financial Context and Valuation

Despite this recovery, the financial landscape remains complex due to falling vaccine sales. Management has provided revenue guidance for 2026 in the range of $59.5 to $62.5 billion. From a valuation perspective, the stock currently trades at a forward price-to-earnings ratio of 9.2, which is notably lower than the industry average of 16.9.

The next key milestone for assessing the company's fundamental performance will arrive on May 5, 2026, with the release of its first-quarter financial results.

Ad

Pfizer Stock: New Analysis - 31 March

Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Pfizer analysis...

US7170811035 | PFIZERS | boerse | 69034370 |